Why India's tier-2/3 towns still trust the local chemist — and what that means for digital health

The funding story the health-tech world mostly missed

Between 2015 and 2023, India's e-pharmacy sector attracted billions of dollars in venture funding. The thesis was straightforward: India has 1.3 billion people, a chronic disease burden of 101 million+ diabetics and 250–315 million hypertensives, and a fragmented, cash-dominated drug retail market ripe for digital disruption.

The reality was more instructive. PharmEasy raised approximately $1.2 billion and saw its valuation collapse from roughly $5 billion to under $500 million — an 80–92% wipeout. Its only profitable subsidiary is Thyrocare, a diagnostics business, not a medicine delivery app. Dunzo, the best-positioned hyperlocal medicine delivery player in India, shut down in January 2025 with approximately $200 million written off. Around 50 pharmacy aggregators launched and folded or were absorbed by inventory-led incumbents.

Yet the neighbourhood chemist did not lose. It's worth asking why.

Three structural reasons — not one UX problem

1. Delivery economics versus urgency physics

The modal medicine purchase in a tier-2 or tier-3 town is small, urgent, over-the-counter, and cash-denominated. The local chemist serves it in 2–10 minutes at zero delivery cost. An e-pharmacy app requires 24–48 hours for non-metro delivery — at a last-mile cost of approximately ₹60–75 per shipment, with an 8–10% failed-delivery rate in underserved pincodes.

For a ₹40 antacid strip, the delivery fee exceeds the medicine cost. No discount can fix this arithmetic, because the chemist's margin is already capped at roughly 16% by DPCO pricing rules. An app must discount 20–50% to drive adoption while also paying logistics on top of that. The unit economics are simply broken for the acute, urgent, small-basket segment that dominates tier-2/3 consumption.

2. Trust and regulatory arbitrage

The local chemist dispenses loose strips — critical for low-income households buying three days of medication at a time. He substitutes a branded drug for a generic at 60–80% savings on the spot, without a consent flow. He runs udhaar (credit) for known customers. He operates with the prescription flexibility that a CDSCO-compliant e-pharmacy cannot afford.

This is not a bug in the system from the consumer's perspective — it is a feature. The app's regulatory compliance (prescription verification, Schedule H/H1 controls, no substitution without consent) is a genuine friction cost relative to the street-level alternative. Apps win when the purchase is large, chronic, and generic-substitutable with a pre-authorized prescription. They lose when the purchase is acute, small, and needs 30 seconds of pharmacist judgment.

3. A lobby-defended supply chain

India has approximately 65,000 drug distributors, organized in a deliberately fragmented regional chain, with the AIOCD representing roughly 12.4 lakh pharmacists who have demonstrated they can shut down national distribution in a single bandh. The May 2026 AIOCD strike — demanding rollback of online pharmacy sales — drew massive nationwide participation. There is no clever API that routes around this lobby.

The supply chain fragmentation is also not transitional. India has 65,000 distributors where the United States covers equivalent volume with just five. This structure serves the interests of too many stakeholders — distributors, chemists, regional stockists, manufacturers with local brand relationships — for consolidation to happen quickly even under regulatory pressure.

What this means for digital health in India

The conclusion that most of the funded players eventually arrived at — too late, in most cases — is that the chemist is not an obstacle to digital health in tier-2/3 India. The chemist is the last-mile node that makes digital health viable.

The business models that are actually profitable in Indian healthtech share a common thread: Practo (20,000+ clinics on its SaaS, B2B model, first EBITDA-positive year in FY25), Thyrocare (77% wholesale diagnostics, no consumer CAC), MediBuddy (75% B2B enterprise revenue, EBITDA-positive Q4 FY26), and MedPlus (profitable at ₹150 Cr PAT in FY25, entirely from dense physical store networks). None of these companies built their moat by disintermediating the local healthcare provider. All of them built on top of, or alongside, the provider network.

The Health9 thesis in one paragraph

Health9 does not fight the local chemist or the neighbourhood doctor. Health9 puts software inside those providers — CuraHIS for hospitals, ClinicPro for clinics, PathologyPro for labs, VedaHR for HR and payroll — at pricing that works for tier-2/3 India's economics. Once those providers are on the Health9 OS, they become the supply buyers for Health9's B2B marketplace and the fulfilment nodes for Health9 Care's chronic-refill, diagnostics, and home-equipment demand layer.

The local chemist who runs udhaar for 200 families in Hooghly is not a problem to solve. He is the trusted node through which a chronic-care subscription should flow. Health9 is the platform underneath him — not the app trying to replace him.